Orbital gallium-67 scintigraphy in Graves' ophthalmopathy

Thyroid

Volumn 12, Issue 7, 2002, Pages 603-608

  Konuk, Onur ^a   Atasever, Tamer ^a   Ünal, Mehmet ^a   Ayvaz, Göksun ^a   Yetkin, Ilhan ^a   Çakir, Nuri ^a   Arslan, Metin ^a   Hasanreisoǧlu, Berati ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GALLIUM CITRATE GA 67; CITRIC ACID; DIAGNOSTIC AGENT; GALLIUM; GALLIUM CITRATE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; EYE DISEASE; FEMALE; GRAVES DISEASE; HUMAN; MALE; PRIORITY JOURNAL; SCINTIGRAPHY; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CONTROL GROUP; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORBIT; PATHOPHYSIOLOGY; ROC CURVE; SCINTILLATION CAMERA; SCINTISCANNING;

ADULT; AGED; CITRATES; CONTROL GROUPS; FEMALE; GALLIUM; GALLIUM RADIOISOTOPES; GAMMA CAMERAS; GRAVES DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; ORBIT; ROC CURVE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0035992866     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072502320288465     Document Type: Article

References (26)

1. Graves' ophthalmopathy: Current concepts regarding pathogenesis and management
2. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach
3. A new ultrasonographic method to detect disease activity and predict response to immunosuppressive treatment in Graves' ophthalmopathy
4. MR T2 relaxation time for the assessment of retrobulbar inflammation in Graves' ophthalmopathy
5. Glycosaminoglycans in thyroid eye disease
6. (111 In-DTPA-D-Phel) octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter of disease activity
7. Eye signs of Graves' disease
8. Management of Graves' ophthalmopathy. Reality and perspectives
9. Classification of the eye changes of Graves' disease
10. Why the NOSPECS clasification of the Graves' eye disease should be abandoned, with suggestion for the characterization of this disease
11. Orbital Graves' disease. A modification of the "NO SPECS" classification
12. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy
13. The measurement of change in Graves' ophthalmopathy
14. Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters
15. Magnetic resonance imaging in thyroid eye disease
16. Indium-111-Pentetreotide scintigraphy in Graves' ophthalmopathy
17. Somatostatin receptors in the orbits
18. Octreotide scintigraphy in thyroidal and orbital Graves' disease
19. Evaluation of immunological mechanisms mediating thyroid associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111-In-Octreotide
20. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease
21. Octreotide scintigraphy is a disease activity parameter in Graves' ophthalmopathy
22. Tc-99 polyclonal human immunoglobulin G imaging in Graves' ophthalmopathy
23. Mechanism of gallium-67 accumulation in inflammatory lesions
24. Orbital accumulation of gallium-67 citrate
25. Tumor and inflammatory disease states
26. The role of octreoscan in thyroid eye disease